New technique removes inoperable abdominal tumors

Share this article:
New Technique Removes Inoperable Abdominal Tumors
New Technique Removes Inoperable Abdominal Tumors

(HealthDay News) -- Multivisceral ex vivo surgery can successfully remove invasive abdominal tumors previously deemed unresectable due to location and vascular involvement, according to a case report published in the May issue of the American Journal of Transplantation.

Tomoaki Kato, M.D., of the Columbia University Medical Center in New York City, and colleagues describe three cases of multivisceral ex vivo surgical procedures in patients with abdominal tumors involving both roots of the celiac and superior mesenteric artery, which are generally considered to be unresectable. Procedures involved temporary removal of the entire abdominal viscera, vascular reconstruction, tumor resection outside the body, and autotransplantation of excised organs.

In all three cases, the researchers found that a complete tumor resection was achieved with negative margins. After 17-, 27-, and 38-month follow-up, all patients survived with no tumor recurrence. Diarrhea, sphincter of Oddi dysfunction, and arterial stenosis were postoperative complications, all of which responded to directed treatments.

"Multivisceral ex vivo surgery applying techniques of deceased donor multivisceral transplantation is feasible in achieving local control of otherwise unresectable abdominal tumors," the authors write. "This surgery is best suitable for locally invasive tumors unresectable because of location and vascular involvement."

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Idelalisib approved by FDA for three types of blood cancer

Idelalisib approved by FDA for three types of ...

Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, but label warns drug may be toxic to the liver.

Physicians cautioned about counterfeit medical devices

Physicians cautioned about counterfeit medical devices

Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices.

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.